Tirzepatide

[GavinParkPT]

Tirzepatide is a dual incretin receptor agonist that targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It's marketed under the brand names Mounjaro for type 2 diabetes and Zepbound for weight loss. Here are some key points about Tirzepatide:

What is Tirzepatide?
Function: By activating GLP-1 and GIP receptors, Tirzepatide helps regulate blood sugar levels, appetite, and gastric emptying.

Forms: Available as a weekly subcutaneous injection using a pre-filled pen.

Uses
Type 2 Diabetes: Helps improve blood sugar control in adults with type 2 diabetes.

Weight Loss: Assists in weight loss for adults with obesity or overweight with weight-related medical conditions.

Benefits
Blood Sugar Control: Enhances glycemic control by increasing insulin secretion and reducing hepatic glucose production.

Weight Loss: Promotes significant weight loss by reducing appetite and slowing gastric emptying.

Cardiovascular Health: May reduce the risk of cardiovascular events in patients with type 2 diabetes.

Dosage and Administration
Typical Dosage: Dosage varies, but common doses include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per week.

Administration: Administered subcutaneously using a pre-filled pen.

Side Effects
Common Side Effects: Nausea, vomiting, diarrhea, and constipation.

Serious Side Effects: Pancreatitis, gallbladder disease, and retinopathy (in diabetic patients).

Important Considerations
Prescription Only: Should be used under medical supervision.

FDA-Approved: Only FDA-approved versions should be used to ensure safety and efficacy